160 related articles for article (PubMed ID: 25350366)
21. Weight gain, metabolic parameters, and the impact of race in aggressive inpatients randomized to double-blind clozapine, olanzapine or haloperidol.
Krakowski M; Czobor P; Citrome L
Schizophr Res; 2009 May; 110(1-3):95-102. PubMed ID: 19269139
[TBL] [Abstract][Full Text] [Related]
22. Profiling of energy metabolism in olanzapine-induced weight gain in rats and its prevention by the CB1-antagonist AVE1625.
Liebig M; Gossel M; Pratt J; Black M; Haschke G; Elvert R; Juretschke HP; Neumann-Haefelin C; Kramer W; Herling AW
Obesity (Silver Spring); 2010 Oct; 18(10):1952-8. PubMed ID: 20168311
[TBL] [Abstract][Full Text] [Related]
23. Double-blind, placebo-controlled investigation of amantadine for weight loss in subjects who gained weight with olanzapine.
Graham KA; Gu H; Lieberman JA; Harp JB; Perkins DO
Am J Psychiatry; 2005 Sep; 162(9):1744-6. PubMed ID: 16135638
[TBL] [Abstract][Full Text] [Related]
24. Olanzapine increases plasma ghrelin level in patients with schizophrenia.
Murashita M; Kusumi I; Inoue T; Takahashi Y; Hosoda H; Kangawa K; Koyama T
Psychoneuroendocrinology; 2005 Jan; 30(1):106-10. PubMed ID: 15358448
[TBL] [Abstract][Full Text] [Related]
25. Orally disintegrating and oral standard olanzapine tablets similarly elevate the homeostasis model assessment of insulin resistance index and plasma triglyceride levels in 12 healthy men: a randomized crossover study.
Vidarsdottir S; Vlug P; Roelfsema F; Frölich M; Pijl H
J Clin Psychiatry; 2010 Sep; 71(9):1205-11. PubMed ID: 20441717
[TBL] [Abstract][Full Text] [Related]
26. The effect of reboxetine co-administration with olanzapine on metabolic and endocrine profile in schizophrenia patients.
Amrami-Weizman A; Maayan R; Gil-Ad I; Pashinian A; Fuchs C; Kotler M; Poyurovsky M
Psychopharmacology (Berl); 2013 Nov; 230(1):23-7. PubMed ID: 23828160
[TBL] [Abstract][Full Text] [Related]
27. The once-daily human GLP-1 analog, liraglutide, reduces olanzapine-induced weight gain and glucose intolerance.
Lykkegaard K; Larsen PJ; Vrang N; Bock C; Bock T; Knudsen LB
Schizophr Res; 2008 Aug; 103(1-3):94-103. PubMed ID: 18579346
[TBL] [Abstract][Full Text] [Related]
28. A randomized, placebo-controlled study of zonisamide to prevent olanzapine-associated weight gain.
McElroy SL; Winstanley E; Mori N; Martens B; McCoy J; Moeller D; Guerdjikova AI; Keck PE
J Clin Psychopharmacol; 2012 Apr; 32(2):165-72. PubMed ID: 22367654
[TBL] [Abstract][Full Text] [Related]
29. A randomized, double-blind, placebo-controlled proof of concept study to evaluate samidorphan in the prevention of olanzapine-induced weight gain in healthy volunteers.
Silverman BL; Martin W; Memisoglu A; DiPetrillo L; Correll CU; Kane JM
Schizophr Res; 2018 May; 195():245-251. PubMed ID: 29158012
[TBL] [Abstract][Full Text] [Related]
30. Decrease of energy expenditure causes weight increase in olanzapine treatment - a case study.
Virkkunen M; Wahlbeck K; Rissanen A; Naukkarinen H; Franssila-Kallunki A
Pharmacopsychiatry; 2002 May; 35(3):124-6. PubMed ID: 12107860
[TBL] [Abstract][Full Text] [Related]
31. Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia.
Kinon BJ; Basson BR; Gilmore JA; Tollefson GD
J Clin Psychiatry; 2001 Feb; 62(2):92-100. PubMed ID: 11247108
[TBL] [Abstract][Full Text] [Related]
32. Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder.
Simpson GM; Glick ID; Weiden PJ; Romano SJ; Siu CO
Am J Psychiatry; 2004 Oct; 161(10):1837-47. PubMed ID: 15465981
[TBL] [Abstract][Full Text] [Related]
33. Olanzapine effects on body composition, food preference, glucose metabolism and insulin sensitivity in the rat.
Smith GC; Vickers MH; Shepherd PR
Arch Physiol Biochem; 2011 Oct; 117(4):241-9. PubMed ID: 21671852
[TBL] [Abstract][Full Text] [Related]
34. Mifepristone reduces weight gain and improves metabolic abnormalities associated with risperidone treatment in normal men.
Gross C; Blasey CM; Roe RL; Belanoff JK
Obesity (Silver Spring); 2010 Dec; 18(12):2295-300. PubMed ID: 20339369
[TBL] [Abstract][Full Text] [Related]
35. Adjunctive effects of aripiprazole on metabolic profiles: comparison of patients treated with olanzapine to patients treated with other atypical antipsychotic drugs.
Wang LJ; Ree SC; Huang YS; Hsiao CC; Chen CK
Prog Neuropsychopharmacol Biol Psychiatry; 2013 Jan; 40():260-6. PubMed ID: 23085073
[TBL] [Abstract][Full Text] [Related]
36. Effect of antipsychotics on peptides involved in energy balance in drug-naive psychotic patients after 1 year of treatment.
Perez-Iglesias R; Vazquez-Barquero JL; Amado JA; Berja A; Garcia-Unzueta MT; Pelayo-Terán JM; Carrasco-Marín E; Mata I; Crespo-Facorro B
J Clin Psychopharmacol; 2008 Jun; 28(3):289-95. PubMed ID: 18480685
[TBL] [Abstract][Full Text] [Related]
37. Chronic administration of olanzapine induces metabolic and food intake alterations: a mouse model of the atypical antipsychotic-associated adverse effects.
Coccurello R; Caprioli A; Ghirardi O; Conti R; Ciani B; Daniele S; Bartolomucci A; Moles A
Psychopharmacology (Berl); 2006 Jul; 186(4):561-71. PubMed ID: 16758241
[TBL] [Abstract][Full Text] [Related]
38. Physical activity is associated with risk factors for chronic disease across adult women's life cycle.
Woolf K; Reese CE; Mason MP; Beaird LC; Tudor-Locke C; Vaughan LA
J Am Diet Assoc; 2008 Jun; 108(6):948-59. PubMed ID: 18502225
[TBL] [Abstract][Full Text] [Related]
39. Randomized, placebo-controlled trial of olanzapine as maintenance therapy in patients with bipolar I disorder responding to acute treatment with olanzapine.
Tohen M; Calabrese JR; Sachs GS; Banov MD; Detke HC; Risser R; Baker RW; Chou JC; Bowden CL
Am J Psychiatry; 2006 Feb; 163(2):247-56. PubMed ID: 16449478
[TBL] [Abstract][Full Text] [Related]
40. Long term treatment with olanzapine mixed with the food in male rats induces body fat deposition with no increase in body weight and no thermogenic alteration.
Minet-Ringuet J; Even PC; Goubern M; Tomé D; de Beaurepaire R
Appetite; 2006 May; 46(3):254-62. PubMed ID: 16551485
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
